Policy & Regulation
Clear Scientific reports positive CS-1103 Phase 2 Results in removing fentanyl from the Body
2 October 2026 - Clear Scientific, Inc., a US-based biopharmaceutical company, on Thursday announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that is c...
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
2 October 2026 - Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new pu...
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
1 October 2026 - Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceuti...
Pfizer's tilrekimig shows significant skin clearance in Phase 2 atopic dermatitis study
1 October 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday reported positive Phase 2 results for investigational tilrekimig (PF-07275315) in adults with moderate-to-severe atopic ...
Sanofi and Regeneron expand antibody alliance with four next-generation immunology programmes
1 October 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) said on Thursday that they have expand...
AFYREN ingredient enables global launch of natural propionic acid skincare product
1 October 2026 - Greentech company AFYREN (Euronext Paris:ALAFY) said on Thursday that it its 100% bio-based, COSMOS-certified propionic acid has enabled the global launch of Esse Barrier Rescue, deve...